ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).

Lorenzo Ferrando,Andrea Vingiani,Anna Garuti,Claudio Vernieri,Antonino Belfiore,Luca Agnelli,Gianpaolo Dagrada,Diana Ivanoiu,Giuseppina Bonizzi,Elisabetta Munzone,Luana Lippolis,Martina Dameri,Francesco Ravera,Marco Colleoni,Giuseppe Viale,Luca Magnani,Alberto Ballestrero,Gabriele Zoppoli,Giancarlo Pruneri

PLoS genetics（2023）

引用 5|浏览42

暂无评分

摘要

ESR1 amplification and activating MAP3K mutations are potential drivers of acquired resistance to adjuvant ETs employing estrogen deprivation in HR+ HER2- BC. MAP3K mutations are associated with worse prognosis in patients with metastatic disease.

查看译文

关键词

esr1 gene amplification,adjuvant endocrine therapies,breast cancer,receptor-positive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要